Compare · CDAK vs MEHA

CDAK vs MEHA

Side-by-side comparison of Codiak BioSciences Inc. (CDAK) and Functional Brands Inc. (MEHA): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CDAK and MEHA operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
  • CDAK has more recent analyst coverage (2 ratings vs 0 for MEHA).
MetricCDAKMEHA
Company
Codiak BioSciences Inc.
Functional Brands Inc.
Price
-
-
Market cap
-
-
1M return
-
-
1Y return
-
-
Industry
Medicinal Chemicals and Botanical Products
Medicinal Chemicals and Botanical Products
Exchange
NASDAQ
NASDAQ
IPO
2020
News (4w)
0
0
Recent ratings
2
0
CDAK

Codiak BioSciences Inc.

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12, an exosome therapeutic candidates, for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; exoASO-NLRP3 for multiple sclerosis, neuropathy, and neurodegeneration; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics, Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Latest CDAK

Latest MEHA